Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)
Technology appraisal
Reference number: TA437
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.